3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Sarcoma, Alveolar Soft Part
1
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
1
Muscle-invasive Bladder Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Sorafenib
5
Nivolumab
3
lenvatinib
2
cabozantinib
2
Ipilimumab
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
durvalumab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
atezolizumab
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma, Hepatocellular
×
atezolizumab
×
Clear all
NCT03434379
2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3
Completed
558 enrolled
48 charts
1 FDA